Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

81. Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause

Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Osphena (ospemifene) Oral Tablets Company: Shionogi Inc. Application No.: 203505 Approval Date: 2/26/2013 Persons with disabilities having problems accessing the PDF files

FDA - Drug Approval Package2013

82. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems

FDA - Drug Approval Package2013

83. Global Consensus Statement on Menopausal Hormone Therapy

Global Consensus Statement on Menopausal Hormone Therapy CLIMACTERIC 2013;16:203–204 © 2013 International Menopause Society and Elsevier Inc. DOI: 10.3109/13697137.2013.771520 This Statement is being simultaneously published in the journals Climacteric and Maturitas , on behalf of the International Menopause Society and The European Menopause and Andropause Society, respectively. Correspondence: T. J. de Villiers, MediClinic Panorama, Parow 7500, South Africa Global Consensus Statement (...) on Menopausal Hormone Therapy T. J. de Villiers , M. L. S. Gass * , C. J. Haines † , J. E. Hall ‡ , R. A. Lobo * * , D. D. Pierroz † † and M. Rees ‡ ‡ MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa; * Department of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA; † Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Prince of Wales

The North American Menopause Society2013

84. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 20, No. 9, pp. 888/902 DOI: 10.1097/gme.0b013e3182a122c2 * 2013 by The North American Menopause Society POSITION STATEMENT Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Abstract Objective: To update and expand the previous position statement (...) of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women. Methods:NAMSsearchedPubMedformedicalliteratureonVVApublishedsincetheir2007positionstatement on the role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women. A panel of ac- knowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on local estrogen as well as on other management options available

The North American Menopause Society2013

85. Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial

Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial 23045575 2012 11 19 2013 03 06 2015 11 19 1527-7755 30 33 2012 Nov 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms (...) in patients with breast cancer: results of a randomized, controlled, multicenter trial. 4124-33 10.1200/JCO.2012.41.8525 The purpose of our study was to evaluate the effect of cognitive behavioral therapy (CBT), physical exercise (PE), and of these two interventions combined (CBT/PE) on menopausal symptoms (primary outcome), body image, sexual functioning, psychological well-being, and health-related quality of life (secondary outcomes) in patients with breast cancer experiencing treatment

EvidenceUpdates2012

86. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement.

Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. DESCRIPTION: Update of the 2005 U.S. Preventive Services Task Force (USPSTF) recommendation statement on hormone therapy for the prevention of chronic conditions in postmenopausal women. METHODS: The USPSTF commissioned a review of the literature to update evidence about the benefits and harms of using menopausal hormone therapy to prevent chronic conditions (...) , as well as whether the benefits and harms of hormone therapy differ by population subgroups defined by age; the presence of comorbid medical conditions; and the type, dose, and method of hormonal delivery. POPULATION: This recommendation applies to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. It does not apply to women who are considering hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal

Annals of Internal Medicine2012

87. Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial

Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial 22936289 2013 01 28 2013 08 13 2016 12 15 1525-1497 28 2 2013 Feb Journal of general internal medicine J Gen Intern Med Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. 193-200 10.1007/s11606-012-2202-6 Paced respiration has been internationally recommended for vasomotor symptom management, despite limited empirical evidence. To evaluate efficacy of a paced (...) respiration intervention against breathing control and usual care control for vasomotor and other menopausal symptoms. A 16-week, 3-group, partially blinded, controlled trial with 2:2:1 randomization and stratification by group (breast cancer, no cancer), in a Midwestern city and surrounding area. Two hundred and eighteen randomized women (96 breast cancer survivors, 122 menopausal women without cancer), recruited through community mailings and registries (29 % minority). Training, home practice support

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

88. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. preventive services taskforce recommendations

Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. preventive services taskforce recommendations Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations Nelson HD (...) trials (which included main trials, the Women’s Health Initiative Memory Study and Women’s Health Initiative Study of Cognitive Aging) were used as the main estimates for each outcome for several reasons including sample size and applicability. The results were presented as hazard ratios (HR) and difference in events per 10,000 women-years, each with 95% confidence intervals (CIs). Planned subgroup analyses were: premature menopause or women with surgical menopause; age of use; doses and modes

DARE.2012

89. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial

Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial 22340966 2012 03 02 2012 04 23 2016 10 19 1474-5488 13 3 2012 Mar The Lancet. Oncology Lancet Oncol. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. 309-18 10.1016/S1470-2045(11)70364-3 Hot flushes and night sweats (HFNS) affect 65-85% of women after breast (...) Randomized Controlled Trial Research Support, Non-U.S. Gov't 2012 02 15 England Lancet Oncol 100957246 1470-2045 0 Antineoplastic Agents IM Health Qual Life Outcomes. 2003;1:41 14521718 Menopause. 2008 Mar-Apr;15(2):310-8 17917611 Menopause. 2008 May-Jun;15(3):469-75 18467951 Psychooncology. 2009 May;18(5):560-3 18646246 Breast Cancer Res Treat. 2009 Jun;115(3):573-80 18670875 BMC Womens Health. 2009;9:15 19500403 Climacteric. 2009 Aug;12(4):310-8 19415540 Cochrane Database Syst Rev. 2010;(9):CD004923

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

91. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium Hiligsmann M, Reginster JY Record Status This is a critical abstract of an economic evaluation (...) . Bibliographic details Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics 2011; 29(10): 895-911 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Belgium; Bone Density Conservation Agents /economics /therapeutic use; Cost-Benefit

NHS Economic Evaluation Database.2012

92. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study.

Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. OBJECTIVE: To characterise symptoms experienced by women during the transition into natural menopause, to classify women into distinct symptom profiles or trajectories, and to relate these profiles to sociodemographic factors and health behaviours. DESIGN: Nationally representative cohort study. SETTING: England, Scotland, and Wales. PARTICIPANTS: 695 women followed-up since birth in 1946 (...) and annually from age 47 to 54 who experienced natural menopause and reported on 20 common health symptoms. MAIN OUTCOME MEASURE: Longitudinal profiles for reported bothersome symptoms. RESULTS: Of 20 individual symptoms, 18 formed into four stable symptom groups: psychological, somatic, vasomotor, and sexual discomfort. Using latent class analyses, all except the somatic group of symptoms showed a clear relation with the timing of menopause for some women. A small proportion of women (10%, n=63) had

BMJ2012 Full Text: Link to full Text with Trip Pro

93. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of secondary plus tertiary prevention of osteoporosis by identifying post-menopausal women who were at increased risk of fractures, compared with tertiary prevention alone. The authors concluded that both prevention strategies were cost-effective compared with no prevention. Secondary plus tertiary prevention was more effective and more

NHS Economic Evaluation Database.2012

94. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations

Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services (...) Task Force Recommendations. Nelson HD, Walker M, Zakher B, Mitchell J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations

Health Technology Assessment (HTA) Database.2012

95. Post-menopausal Hormone Treatment Update (DOPS, KEEPS)

Post-menopausal Hormone Treatment Update (DOPS, KEEPS) Post Post- -menopausal Hormonal Tx menopausal Hormonal Tx Is the pendulum swinging again? Is the pendulum swinging again? ? ? Pre Pre- -2002 2002 Nurses Health Study (observational) Nurses Health Study (observational) – – Hormones widely recommended for post Hormones widely recommended for post- -menopausal (PM) menopausal (PM) women; lots of potential benefit including women; lots of potential benefit including p p heart disease heart (...) ) ) – – PM hormones aren PM hormones aren’ ’t so bad after all, if used soon after t so bad after all, if used soon after menopausal onset, in younger women, for short time. In fact menopausal onset, in younger women, for short time. In fact one underpowered study says they may even be good. one underpowered study says they may even be good. Another, underpowered study suggests safety may be related Another, underpowered study suggests safety may be related to formulation used. Some reassured; others

RxFiles2012

96. The 2012 Hormone Therapy Position Statement of The North American Menopause Society

The 2012 Hormone Therapy Position Statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 19, No. 3, pp. 257/271 DOI: 10.1097/gme.0b013e31824b970a * 2012 by The North American Menopause Society POSITION STATEMENT The 2012 Hormone Therapy Position Statement of The North American Menopause Society Abstract Objective: This position statement aimed to update the evidence-based position statement published by The North American Menopause (...) Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset. Methods: An Advisory Panel of expert clinicians and researchers in the field of women’s health was enlisted to review the 2010 NAMS position statement

The North American Menopause Society2012

97. Compounded Bioidentical Menopausal Hormone Therapy

Compounded Bioidentical Menopausal Hormone Therapy Compounded Bioidentical Menopausal Hormone Therapy - ACOG Menu ▼ Compounded Bioidentical Menopausal Hormone Therapy Page Navigation ▼ Number 532, August 2012 (Reaffirmed 2016, Replaces No. 387, November 2007 and No. 322, November 2005) Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee This document reflects emerging clinical and scientific advances as of the date issued and is subject (...) to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Compounded Bioidentical Menopausal Hormone Therapy ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall effectiveness, has reinforced its usefulness for short-term treatment of menopausal symptoms. Menopausal therapy has been provided

American College of Obstetricians and Gynecologists2012

98. Compounded bioidentical menopausal hormone therapy: a committee opinion

Compounded bioidentical menopausal hormone therapy: a committee opinion Compounded bioidentical menopausal hormone therapy American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and American Society for Reproductive Medicine Practice Committee AmericanCollegeofObstetriciansandGynecologists, Washington, DC; andAmericanSocietyforReproductiveMedicine, Birmingham, Alabama Although improvement in long-term health is no longer an indication for menopausal hormone (...) marketingandmediapromotionofcompoundedbioidenticalhormonalpreparationsassafeandeffectivealternativestoconventional menopausal hormone therapy, have led to a recent increase in the popularity of compounded bioidentical hormones as well as an in- creaseinquestionsabouttheuseofthesepreparations.Notonlyisevidencelackingtosupportsuperiorityclaimsofcompoundedbio- identical hormones over conventional menopausal hormone therapy, but these claims also pose the additional risks ofvariable purity and potency and lack ef?cacy and safety data. The Committee on Gynecologic Practice of the American College

Society for Assisted Reproductive Technology2012

99. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data.

Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. OBJECTIVES: To use changes in heart disease mortality rates with age to investigate the plausibility of attributing women's lower heart disease mortality than men to the protective effects of premenopausal sex hormones. DESIGN: Modelling study of longitudinal mortality data with models assuming (i) a linear association between mortality rates and age (...) <0.001). We found similar results in US data. CONCLUSIONS: Proportional age related changes in ischaemic heart disease mortality, suggesting a loss of reparative reserve, fit longitudinal mortality data from England, Wales, and the United States better than absolute age related changes in mortality. Acceleration in male heart disease mortality at younger ages could explain sex differences rather than any menopausal changes in women.

BMJ2011 Full Text: Link to full Text with Trip Pro